

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 162 207 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
12.12.2001 Bulletin 2001/50

(51) Int Cl.7: **C07K 14/575, A61K 38/22**

(21) Application number: **01114132.2**

(22) Date of filing: **19.11.1992**

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
SE**

(30) Priority: **19.11.1991 US 794266**

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
92924442.4 / 0 567 626

(71) Applicant: **AMYLIN PHARMACEUTICALS, INC.**
San Diego California 92121 (US)

(72) Inventors:
• **Gaeta, Laura S. L.**
Olivenhain, CA 92024 (US)
• **Jones, Howard**
Poway, CA 92064 (US)

• **Albrecht, Elisabeth**
San Diego, CA 92126 (US)

(74) Representative: **Goldin, Douglas Michael**
J.A. KEMP & CO.
14 South Square
Gray's Inn
London WC1R 5JJ (GB)

Remarks:

- This application was filed on 11 - 06 - 2001 as a divisional application to the application mentioned under INID code 62.
- The sequence listing, which is published as annex to the application documents, was filed after the date of filing. The applicant has declared that it does not include matter which goes beyond the content of the application as filed.

(54) **Amylin agonist peptides and uses therefor**

(57) Agonist analogues of amylin and related pharmaceutical compositions are provided which are useful

for the treatment of diabetes and other insulin-requiring states.

EP 1 162 207 A1

DescriptionField Of The Invention

5 **[0001]** The field of the invention is medicine, particularly the treatment and prevention of hypoglycemic conditions and other conditions in which enhanced amylin action is of benefit, including insulin-requiring states such as diabetes mellitus. More specifically, the invention relates to the preparation and use of agonist analogues of the peptide hormone amylin.

Description Of Related Art And Introduction To The Invention

10 **[0002]** Diabetes mellitus is a serious metabolic disease that is defined by the presence of chronically elevated levels of blood glucose (hyperglycemia). This state of hyperglycemia is the result of a relative or absolute lack of activity of the peptide hormone, insulin. Insulin is produced and secreted by the β cells of the pancreas. Insulin is reported to promote glucose utilization, protein synthesis, and the formation and storage of neutral lipids. Glucose, the principal source of carbohydrate energy, is stored in the body as glycogen, a form of polymerized glucose, which may be converted back into glucose to meet metabolism requirements. Under normal conditions, insulin is secreted at both a basal rate and at enhanced rates following glucose stimulation, all to maintain metabolic homeostasis by the conversion of glucose into glycogen.

20 **[0003]** The term diabetes mellitus encompasses several different hyperglycemic states. These states include Type 1 (insulin-dependent diabetes mellitus or IDDM) and Type 2 (non-insulin-dependent diabetes mellitus or NIDDM) diabetes. The hyperglycemia present in individuals with Type 1 diabetes is associated with deficient, reduced, or non-existent levels of insulin which are insufficient to maintain blood glucose levels within the physiological range. Treatment of Type 1 diabetes involves administration of replacement doses of insulin, generally by the parenteral route. The hyperglycemia present in individuals with Type II diabetes is initially associated with normal or elevated levels of insulin; however, these individuals are unable to maintain metabolic homeostasis due to a state of insulin resistance in peripheral tissues and liver and, as the disease advances, due to a progressive deterioration of the pancreatic (3 cells which are responsible for the secretion of insulin. Thus, initial therapy of Type 2 diabetes may be based on diet and lifestyle changes augmented by therapy with oral hypoglycemic agents such as sulfonylureas. Insulin therapy is often required, however, especially in the latter stages of the disease, in attempting to produce some control of hyperglycemia and minimize complications of the disease. Thus, many Type 2 diabetics ultimately require insulin in order to survive.

30 **[0004]** Amyloid is the name given to extracellular deposits of β sheet protein filaments. Deposits of amyloid material have been reported to be found in pancreas of patients with Type 2 diabetes mellitus. Other studies have indicated that the degree of amyloid depositions increases with the degree of hyperglycemia in humans and the severity of Type 2 diabetes. Chemical analysis of pancreatic amyloid led to the surprising and unexpected discovery of the peptide hormone, amylin. Clark, A., et al., Lancet ii: 231-234 (1987). This peptide was discovered to be comprised of 37 amino acids, none of which are acidic residues, to have a disulfide linkage between the cysteine residues at positions 2 and 7, and to be C-terminally amidated. Amylin is the major protein constituent of the amyloid which is reported to be found in the pancreatic islets of Langerhans in patients with type 2 diabetes mellitus.

40 **[0005]** It has been reported that the presence of both the intramolecular cystine bridge and the carboxy-terminal amide group in the peptide structure of the synthetic molecule yield the greatest biological activity to inhibit glycogen synthesis in skeletal muscle. E.g., Cooper, G.J.S., et al., Proc. Natl. Acad. Sci. (USA) 84:8628-8632 (1987); Cooper G.J.S., et al., in Diabetes 1988, ed. Larkins, R., Zimmet, P. & Chisholm, D. (Elsevier, Amsterdam), pp. 493-496 (1989). The amino acid sequence of amylin (see Figure 1) has 46% homology with human calcitonin gene related peptide 2 (CGRP-2).

45 **[0006]** One report states that a limited segment of the amylin molecule, residues 20-29, is a potential contributor toward amyloid fibril formation in the islets of Langerhans in Type 2 diabetes mellitus. Glenner et al., Biochem. Biophys. Res Commun. 155:608-614 (1988). It has also been reported that amino acid sequence differences between amylin from certain mammalian species occur in this region, and further investigation has focused on identifying residues linked to amyloid formation. Westermarck et al., Proc. Natl. Acad. Sci. (USA) 87: 5036-5040 (1990). The study of Westermarck et al. reported attempts to synthesize various 20-29 amino acid segments of amylin sequences from different species followed by a comparison of their ability to form amyloid fibrils. It was proposed that the residues 25-29 of human amylin were the most strongly amyloidogenic and that the proline-for-serine substitution in position 28, as in several rodent species, significantly inhibited fibril formation in the studied decapeptides.

55 **[0007]** Amylin is a complex peptide, and the synthesis of bioactive preparations of amylin is laborious. Amylin has also been found to have limited solubility and limited stability in solution. We have found that rat amylin has a higher solubility and stability in solution than human amylin. This may be due in some measure, although this is not known, to the different aggregation properties of the amylin from different species. Only the human, non-human primate, and

cat species of amylin have been reported to aggregate to form islet amyloid in vivo. The sequences of amylin now reported to have been isolated from a number of species are set forth in Figure 2.

[0008] In Type I diabetes, amylin levels are severely reduced or are nonexistent when compared to normal controls. In the disease state of Type I diabetes mellitus, the β -cells, which are the producers of insulin and amylin, have been destroyed by an autoimmune process. Amylin has been proposed to be useful in the treatment of diabetes mellitus and hypoglycemia, including insulin-induced hypoglycemia. It has also been proposed that the co-administration of insulin with amylin is a superior therapy to the existing administration of insulin alone, and that coadministration of amylin with glucagon for the treatment of hypoglycemia is a superior therapy to the existing administration of glucagon alone. It would be useful to provide, for such purposes and others, less complicated compounds that have the activities of native human amylin, as well as compounds which may show enhanced solubility and/or stability over native human amylin. Such compounds are described and claimed herein.

Summary Of The Invention

[0009] The present invention is directed to novel analogues of the peptide hormone amylin. These compounds mimic the effects of amylin, and are referred to as amylin agonists or as agonist analogues of amylin.

[0010] The invention is also directed to pharmaceutical compositions comprising the agonist analogues of the present invention, and to methods of treatment and prevention of hypoglycemic conditions and other conditions in which enhanced amylin action is of benefit, including insulin-requiring states such as diabetes mellitus, comprising administering an agonist analogue of amylin to an animal (alone or in conjunction with an insulin or a glucagon).

Definitions

[0011] As used herein, the following terms have the following meanings unless expressly stated to the contrary:

The term "alkyl" refers to both straight- and branched-chain alkyl groups. The term "lower alkyl" refers to both straight- and branched-chain alkyl groups having a total of from 1 to 6 carbon atoms and includes primary, secondary and tertiary alkyl groups. Typical lower alkyls include, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, n-hexyl, and the like.

The term "aryl" refers to carbocyclic aromatic groups of 6 to 14 carbon atoms such as phenyl and naphthyl, as well as heterocyclic aromatic groups containing 1 to 3 heteroatoms (nitrogen, oxygen, sulfur, etc.) such as pyridyl, triazolopyrazine, pyrimidine and the like.

The term "aralkyl" refers to an "aryl" group of 6 to 10 carbon atoms directly attached to an "alkyl" group of 1 to 4 carbon atoms and includes for example benzyl, p-chlorobenzyl, p-methylbenzyl, and 2-phenylethyl.

The term "cycloalkyl" refers to cyclic alkyl groups of 5 to 8 carbon atoms.

Brief Description Of The Drawings

[0012]

FIG. 1 depicts the amino acid sequence of human amylin.

FIG. 2 depicts a comparison of amino acid sequences of amylin isolated from several mammals.

FIG. 3 depicts the amino acid sequence of novel amylin agonist peptides.

Detailed Description Of The Invention

[0013] According to the present invention, novel agonist analogues of amylin are provided. These analogues are useful as agonists of amylin, including as hyperglycemics, and may be represented by Figure 3.

[0014] In one aspect, the present invention is directed to agonist analogues of Figure 3, wherein A_1 is hydrogen, Lys, Ser, Ala, des- α -amino Lys, or acetylated Lys; B_1 is Ala, Ser or Thr; C_1 is Val, Leu or Ile; D_1 is His or Arg; E_1 is Ser or Thr; F_1 is Ser, Thr, Gln or Asn; G_1 is Asn, Gln or His; H_1 is Phe, Leu or Tyr; I_1 is Ala or Pro; J_1 is Ile, Val, Ala or Leu; K_1 is Ser, Pro, Leu, Ile or Thr; L_1 is Ser, Pro or Thr; M_1 is Asn, Asp or Gln; X and Y are independently selected residues having side chains which are chemically bonded to each other to form an intramolecular linkage; and Z is hydroxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy or aralkyloxy; provided that (a) when A_1 is Lys, B_1 is Ala, C_1 is Val, D_1 is His, E_1 is Ser, F_1 is Ser, G_1 is Asn, H_1 is Phe, I_1 is Ala, J_1 is Ile, K_1 is Ser, L_1 is Ser, and M_1 is Asn; (b) when A_1 is Lys, B_1 is Ala, C_1 is Ile, D_1 is Arg, E_1 is Ser, F_1 is Ser, G_1 is Asn, H_1 is Leu, I_1 is Ala, J_1 is Ile, K_1 is Ser, L_1 is Pro, and M_1 is Asn; (c) when A_1 is Lys, B_1 is Ala, C_1 is Val, D_1 is Arg, E_1 is Thr, F_1 is Ser, G_1 is Asn, H_1 is Leu, I_1 is Ala, J_1 is Ile, K_1 is Ser, L_1 is Pro, and M_1 is Asn; (d) when A_1 is Lys, B_1 is Ala, C_1

is Val, D₁ is Arg, E₁ is Ser, F₁ is Ser, G₁ is Asn, H₁ is Leu, I₁ is Pro, J₁ is Val, K₁ is Pro, L₁ is Pro, and M₁ is Asn; (e) when A₁ is Lys, B₁ is Ala, C₁ is Val, D₁ is His, E₁ is Ser, F₁ is Asn, G₁ is Asn, H₁ is Leu, I₁ is Pro, J₁ is Val, K₁ is Ser, L₁ is Pro and M₁ is Asn; or (f) when A₁ is Lys, B₁ is Thr, C₁ is Val, D₁ is Arg, E₁ is Ser, F₁ is Ser, G₁ is His, H₁ is Leu, I₁ is Ala, J₁ is Ala, K₁ is Leu, L₁ is Pro and M₁ is Asp; then one or more of any of A₁ to M₁ is not an L-amino acid and Z is not amino.

[0015] Suitable side chains for X and Y include groups derived from alkyl sulfhydryls which may form disulfide bonds; alkyl acids and alkyl amines which may form cyclic lactams; alkyl aldehydes or alkyl halides and alkylamines which may condense and be reduced to form an alkyl amine bridge; or side chains which may be connected to form an alkyl, alkenyl, alkynyl, ether or thioether bond. Preferred alkyl chains include lower alkyl groups having from about 1 to about 6 carbon atoms.

[0016] An additional aspect of the present invention is directed to agonist analogues of Figure 3 which are not bridged, and wherein X and Y are independently selected from Ala, Ser, Cys, Val, Leu and Ile or alkyl, aryl, or aralkyl esters and ethers of Ser or Cys.

[0017] Biologically active derivatives of the above Figure 3 agonist analogues are also included within the scope of this invention in which the stereochemistry of individual amino acids may be inverted from (L)/S to (D)/R at one or more specific sites.

[0018] Also included within the scope of this invention are the agonist analogues modified by glycosylation of Asn-, Ser and/or Thr residues.

[0019] Biologically active agonist analogues of amylin are included within the scope of this invention which contain less peptide character. Such peptide mimetics may include, for example, one or more of the following substitutions for -CO-NH-amide bonds: depsipeptides (-CO-O-), iminomethylenes (-CH₂-NH-), *trans*-alkenes (-CH=CH-), β -enaminonitriles (-C(=CH-CN)-NH-), thioamides (-CS-NH-), thiomethylenes (-S-CH₂- or -CH₂-S-), methylenes (-CH₂-CH₂-) and retro-amides (-NH-CO-).

[0020] Compounds of this invention form salts with various inorganic and organic acids and bases. Such salts include salts prepared with organic and inorganic acids, for example, HCl, HBr, H₂SO₄, H₃PO₄, trifluoroacetic acid, acetic acid, formic acid, methanesulfonic acid, toluenesulfonic acid, maleic acid, fumaric acid and camphorsulfonic acid. Salts prepared with bases include, for example, ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkali earth salts (such as calcium and magnesium salts). Acetate, hydrochloride, and trifluoroacetate salts are preferred.

[0021] The salts may be formed by conventional means, as by reacting the free acid or base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the ions of an existing salt for another ion on a suitable ion exchange resin.

[0022] The compounds of the invention include various stereoisomers. In the preferred compounds of this invention, the chiral centers on the peptide backbone are all S.

[0023] Compounds of the present invention may be prepared by using certain conventional coupling reactions known in the peptide art. The analogues of this invention are prepared by successively adding the desired amino acid to a growing peptide chain. Typically, an α -N-carbamoyl protected amino acid and an amino acid attached to the growing peptide chain on a resin support are reacted at room temperature in an inert solvent such as N-methylpyrrolidone, dimethylformamide or methylene chloride in the presence of coupling agents such as dicyclohexylcarbodiimide 1-hydroxybenzotriazole in the presence of a base such as diisopropylethylamine. The α -N-carbamoyl protecting group is removed from the resultant peptide with a reagent such as trifluoroacetic acid or piperidine, and the coupling reaction repeated with the next desired N-protected amino acid. Suitable N-protecting groups are known in the art, with t-butyloxycarbonyl herein preferred.

[0024] Certain preferred methods for synthesis are described in the commonly-assigned copending and commonly assigned patent application Serial No. 667,040 ("Synthetic Preparation of Amylin and Amylin Analogs", filed March 8, 1991). These methods provide for solid phase synthesis of a peptide which comprises amylin or an amylin analog which has enhanced biological activity and is substantially free of deletion and other contaminating peptides wherein said peptide is synthesized using successive synthesis cycles, whereby in each such synthesis cycle, a designated amino acid is added to a growing peptide chain attached to an insoluble resin support by formation of a peptide linkage between an α -amino group of the growing peptide chain and on α -carboxyl of the designated amino acid; and wherein each synthesis cycle comprises: (a) treating the growing peptide chain under α -amino deprotecting conditions to remove an α -amino group; (b) activating the α -carboxyl group of the α -amino protected designated amino acid; (c) contacting the growing peptide chain and the designated amino acid under coupling conditions to form a peptide linkage between the free α -amino for the peptide chain and the activated α -carboxyl of the designated amino acid; and (d) repeating steps (b) and (c) if the coupling efficiency of step (c) is less than about 97%. It is preferred to repeat steps (b) and (c) if the coupling efficiency is less than about 99%. In another preferred aspect, steps (b) and (c) are repeated in each synthesis cycle. Optionally, the coupling efficiency is measured after each coupling step.

[0025] Suitable coupling conditions include use of a solvent system which maximizes swelling of the solid support, minimizes secondary structure elements of the peptide chain during synthesis cycles, and minimizes intrapeptide and interpeptide hydrogen bonding. Preferably the synthesis cycle includes a capping step after the coupling step(s) where-
 5 using appropriate protected α -amino acids to give amylin or an amylin analog of specified sequence. After completions of the successive synthesis cycles, said amylin or amylin analog is cleaved from the solid support. It is preferred that the cysteine residues of the peptide chain are selectively deprotected and an intramolecular disulfide bond is formed before cleaving the peptide bond from the solid support.

[0026] Suitable α -amino protective groups include t-butoxycarbonyl and 9-fluorenylmethoxycarbonyl. In one preferred aspect, when t-butoxycarbonyl is used as the α -amino protecting group, the α -carboxyl groups are activated using dicyclohexylcarbodiimide and 1-hydroxybenzotriazole to form 1-hydroxybenzotriazole esters. A particularly preferred solvent system comprise N-methylpyrrolidone.

[0027] The preparation of certain agonist analogues of amylin within the invention is described in Examples 1 to 17 herein. In addition, other agonist analogues which may be prepared according to the above procedures are set forth
 15 in Table II herein. The compounds of the invention may also be prepared using recombinant DNA techniques, using methods now known in the art. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor (1989).

[0028] The nomenclature of the compounds of the present invention can be used to indicate both the peptide that the sequence is based on and the modifications made to any basic peptide amylin sequence, such as human amylin. An amino acid preceded by a superscript number indicates that the named amino acid replaces the amino acid normally present at the amino acid position of the superscript in the basic amino acid sequence. For example, "¹⁸Arg^{25,28}Pro-h-amylin" refers to a peptide based on the sequence of "h-amylin" or "human-amylin" having the following substitutions: Arg replacing His at residue 18, Pro replacing Ala at residue 25 and Pro replacing Ser at residue 28. The term "des-¹Lys-h-amylin" refers to a peptide based on the sequence of human amylin, with the first, or N-terminal, amino acid deleted.

[0029] The agonist analogues of amylin of this invention are useful in view of their pharmacological properties. In particular, compounds of this invention possess activity as amylin agonist agents, as will be evidenced by activity in the receptor binding assay and the soleus muscle assay described in Examples 18 and 19, respectively. Amylin agonist activity of compounds may also be assessed by the ability to induce hyperlactemia and/or hyperglycemia in mammals. In addition to the description of compounds pursuant to Figure 3, certain preferred compounds are set forth in Table
 30 I. The preferred compounds des-¹Lys-h-amylin; ²⁸Pro-h-amylin, ^{25,28,29}Pro-h-amylin, ¹⁸Arg^{25,28}Pro-h-amylin, and des-¹Lys¹⁸Arg^{25,28}Pro-h-amylin, all show amylin activity *in vivo* in treated test animals, provoking marked hyperlactemia followed by hyperglycemia. In addition to having activities characteristic of amylin, certain of the preferred compounds of the invention have also been found to possess more desirable solubility and stability characteristics when compared to human amylin. These preferred compounds include ²⁵Pro²⁶Val^{28,29}Pro-h-amylin, ^{25,28,29}Pro-h-amylin, and ¹⁸Arg^{25,28}Pro-h-amylin.

[0030] Compounds described herein which are especially preferred include ¹⁸Arg^{25,28}Pro-h-amylin, des-¹Lys ¹⁸Arg^{25,28}Pro-h-amylin, ¹⁸Arg^{25,28,29}Pro-h-amylin, des-¹Lys¹⁸Arg^{25,28,29}Pro-h-amylin, ^{25,28,29}Pro-h-amylin, des-¹Lys^{25,28,29}Pro-h-amylin, and ²⁵Pro²⁶Val^{28,29}Pro-h-amylin. Still further amylin agonist peptide compounds are listed in Table II. They include:

²³Leu²⁵Pro²⁶Val^{28,29}Pro-h-amylin;
²³Leu²⁵Pro²⁶Val²⁸Pro-h-amylin;
 des-¹Lys²³Leu²⁵Pro²⁶Val²⁸Pro-h-amylin;
¹⁸Arg²³Leu²⁵Pro²⁶Val²⁸Pro-h-amylin ;
 45 ¹⁸Arg²³Leu^{25,28,29}Pro-h-amylin;
¹⁸Arg²³Leu^{25,28}Pro-h-amylin;
¹⁷Ile²³Leu^{25,28,29}Pro-h-amylin;
¹⁷Ile^{25,28,29}Pro-h-amylin;
 des-¹Lys¹⁷Ile²³Leu^{25,28,29}Pro-h-amylin;
 50 ¹⁷Ile¹⁸Arg²³Leu-h-amylin;
¹⁷Ile¹⁸Arg²³Leu²⁶Val²⁹Pro-h-amylin;
¹⁷Ile¹⁸Arg²³Leu²⁵Pro²⁶Val^{28,29}Pro-h-amylin;
¹³Thr²¹His²³Leu²⁶Ala²⁸Leu²⁹Pro³¹Asp-h-amylin;
¹³Thr²¹His²³Leu²⁶Ala²⁹Pro³¹Asp-h-amylin;
 55 des-¹Lys¹³Thr²¹His²³Leu²⁶Ala²⁸Pro³¹Asp-h-amylin;
¹³Thr¹⁸Arg²¹His²³Leu²⁶Ala²⁹Pro³¹Asp-h-amylin;
¹³Thr¹⁸Arg²¹His²³Leu^{28,29}Pro³¹Asp-h-amylin; and
¹³Thr¹⁸Arg²¹His²³Leu²⁵Pro²⁶Ala^{28,29}Pro³¹Asp-h-amylin;

[0031] The compounds of this invention can be combined with pharmaceutical carriers to prepare pharmaceutical forms suitable for parenteral administration. Experimental responses of the compounds support the clinical application of such pharmaceutical compositions in the treatment of diabetes mellitus and other insulin-requiring states, as well as in the prevention and treatment of episodes of hypoglycemia. The compounds of this invention can also be combined with insulin for the treatment of diabetes mellitus and other insulin-requiring states. By "insulin" is meant a polypeptide or its equivalent useful in regulation of blood glucose levels. A general description of such insulins is provided in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th Ed., Pergamon Press (1990). Such insulins can be fast acting, intermediate acting, or long acting. Various derivatives of insulin exist and are useful in this invention. See, e.g., U.S. Patent Nos. 5,049,547, 5,028,587, and 5,016,643. Insulin peptides are also useful (see, e.g., U.S. Patent No. 5,008,241), as are analogues (see, e.g., U.S. Patent No. 4,992,417 and 4,992,418). Such compositions can be administered by any standard route, including nasal administration (see, e.g., U.S. Patent Nos. 4,988,512 and 4,985,242, and 2 BioWorld Today, No. 125 (1991)). The compounds of this invention are also useful in combination with a glucagon for the prevention and treatment of hypoglycemia. See Young et al., U.S. Application Serial No. 07/640,478, filed January 10, 1991, entitled "Hyperglycemic Compositions," which is incorporated herein by reference.

[0032] Compositions or products of the invention may conveniently be provided in the form of solutions suitable for parenteral (including intravenous, intramuscular and subcutaneous) or nasal or oral administration. In many cases, it will be convenient to provide an agonist analogue of amylin and an insulin or glucagon in a single composition or solution for administration together. In other cases, it may be more advantageous to administer an insulin or a glucagon separately from said agonist analogue. A suitable administration format may best be determined by a medical practitioner for each patient individually. Suitable pharmaceutically acceptable carriers and their formulation are described in standard formulation treatises, e.g., Remington's Pharmaceutical Sciences by E.W. Martin. See also Wang, Y.J. and Hanson, M.A. "Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers," Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2S (1988). Suitable formulations including insulin or glucagon are known in the art.

[0033] The agonist preparations of the invention may be stabilized at neutral pH. Since the products of the invention are amphoteric they may be utilized as free bases, as acid addition salts or as metal salts. The salts must, of course, be pharmaceutically acceptable, and these will include metal salts, particularly alkali and alkaline earth metal salts, e.g., potassium or sodium salts. A wide variety of pharmaceutically acceptable acid addition salts are available, as described above. These include those prepared from both organic and inorganic acids, preferably mineral acids. Typical acids which may be mentioned by way of example include citric, succinic, lactic, hydrochloric and hydrobromic acids. Such products are readily prepared by procedures well known to those skilled in the art.

[0034] The products of the invention will normally be provided as parenteral compositions for injection or infusion. They can, for example, be suspended in an inert oil, suitably a vegetable oil such as sesame, peanut, or olive oil. Alternatively, they can be suspended in an aqueous isotonic buffer solution at a pH of about 5.6 to 7.4. Useful buffers include sodium citrate-citric acid and sodium phosphate-phosphoric acid. A form of repository or "depot" slow release preparation may be used so that therapeutically effective amounts of the preparation are delivered into the bloodstream over many hours or days following transdermal injection.

[0035] The desired isotonicity may be accomplished using sodium chloride or other pharmaceutically acceptable agents such as dextrose, boric acid, sodium tartrate, propylene glycol, polyols (such as mannitol and sorbitol), or other inorganic or organic solutes. Sodium chloride is preferred particularly for buffers containing sodium ions.

[0036] If desired, solutions of the above compositions may be thickened with a thickening agent such as methyl cellulose. They may be prepared in emulsified form, either water in oil or oil in water. Any of a wide variety of pharmaceutically acceptable emulsifying agents may be employed including, for example, acacia powder, a non-ionic surfactant (such as a Tween), or an ionic surfactant (such as alkali polyether alcohol sulfates or sulfonates, e.g., a Triton).

[0037] The therapeutically useful compositions of the invention are prepared by mixing the ingredients following generally accepted procedures. For example, the selected components may be simply mixed in a blender or other standard device to produce a concentrated mixture which may then be adjusted to the final concentration and viscosity by the addition of water or thickening agent and possibly a buffer to control pH or an additional solute to control tonicity.

[0038] For use by the physician, the compositions will be provided in dosage unit form containing an amount of an agonist compound with or without insulin or glucagon which will be effective in one or multiple doses to control or reestablish blood sugar at the selected level. Therapeutically effective amounts of an agonist analogue of amylin as described herein for the treatment of hypoglycemia are those that increase blood sugar levels, preferably to above 80 mg/dl. Therapeutically effective amounts of such agonist analogues for the treatment of diabetes mellitus and other insulin-requiring states are those sufficient to provide for reduced incidence of insulin overdose or undesired hypoglycemia. As will be recognized by those in the field, an effective amount of therapeutic agent will vary with many factors including the age and weight of the patient, the patient's physical condition, the blood sugar level to be obtained, and other factors. Typical dosage units for treatment of diabetes mellitus will contain from about 0.1 to 5 mg of an amylin agonist compound and, if desired, about 0.5 to about 10 mg of an insulin. Typical dosage units for the treatment of

hypoglycemia will contain about 0.5 to 1.0 mg of an amylin agonist compound and, if desired, the art recognized quantity, or less, of a glucagon.

[0039] As set forth above, compositions useful in the invention are formulated by standard procedure. These compositions are also administered by standard procedure. Suitable doses are readily determined by those in the art, examples of which are provided above.

[0040] To assist in understanding the present invention, the following examples are included which describe the results of a series of experiments. The following examples relating to this invention should not, of course, be construed as specifically limiting the invention. Such variations of the invention, now known or later developed, which would be within the purview of one skilled in the art are considered to fall within the scope of the present invention as hereinafter claimed.

Examples

Example 1

Preparation of ²⁸Pro-human-Amylin

[0041] Solid phase synthesis of this analogue of human ("h-") amylin using methylbenzhydrylamine anchor-bond resin and N^α-Boc/benzyl-side chain protection was carried out by standard peptide synthesis methods. The 2,7-[disulfide]amylin-MBHA-resin was obtained by treatment of Ac^αm-protected cysteines with thallium (III) trifluoroacetate in trifluoroacetic acid. After cyclization was achieved the resin and side chain protecting groups were cleaved with liquid hydrofluoric acid ("HF") in the presence of dimethylsulfide and anisole. The ²⁸Pro-h-amylin was purified by preparative HPLC. The peptide was found to be homogeneous by analytical HPLC and capillary electrophoresis and the structure confirmed by amino acid analysis and sequence analysis. The product gave the desired mass ion. FAB mass spec: (M+I)/e=3914.

Example 2

Preparation of ²⁵Pro²⁶Val^{28,29}Pro-h-Amylin

[0042] Solid phase synthesis of this amylin analogue using methylbenzhydrylamine anchor-bond resin and N^α-Boc/benzylside chain protection was carried out by standard peptide synthesis methods. The 2,7-[disulfide] amylin-MBHA-resin was obtained by treatment with thallium (III) trifluoroacetate in trifluoroacetic acid. After cyclization was achieved the resin and side chain protecting groups were cleaved with liquid HF in the presence of dimethylsulfide and anisole. The ²⁵Pro²⁶Val^{28,29}Pro-h-amylin was purified by preparative HPLC. The peptide was found to be homogeneous by analytical HPLC and capillary electrophoresis and the structure confirmed by amino acid analysis and sequence analysis. The product gave the desired mass ion. FAB mass spec: (M+I)/e=3936.

Example 3

Preparation of 2,7Cyclo-[²Asp,⁷Lys]-h-Amylin

[0043] Solid phase synthesis of this amylin analogue using methylbenzhydrylamine anchor-bond resin and N^α-Boc/benzylside chain protection was carried out by standard peptide synthesis methods. ²Asp and ⁷Lys were introduced with Boc-²Asp (Fmoc)-OH and Boc-⁷Lys(Fmoc)-OH. Following selective side-chain deprotection with piperidine the side-chain to side-chain (²Asp-⁷Lys) cyclization was carried out using benzotriazol-1-yl-oxy-tris (dimethylamino)-phosphonium hexafluorophosphate (BOP reagent). Cyclization was as described in Di Maio, J., et al., J. Med. Chem. 33: 661-667 (1990); Felix, A.M., et al., Int J. Pent. Prot. Res. 32:441 (1988). The 2,7cyclo-[²Asp,⁷Lys] amylin-MBHA-resin obtained after cyclization was cleaved with liquid HF in the presence of dimethylsulfide and anisole. The 2,7cyclo-(²Asp,⁷Lys)-h-amylin was purified by preparative HPLC. The peptide was found to be homogeneous by analytical HPLC and capillary electrophoresis and the structure confirmed by amino acid analysis and sequence analysis. FAB mass spec: (M+I)/e=3925.

Example 4

Preparation of des-¹Lys-h-Amylin

[0044] Solid phase synthesis of des-¹Lys-h-amylin (also represented as ²⁻³⁷h-amylin) using methylbenzhydrylamine

anchor-bond resin and N^a-Boc/benzyl-side chain protection was carried out by standard peptide synthesis methods. The 2,7-[disulfide]amylin-MBHA-resin was obtained by treatment of Acm-protected cysteines with thallium (III) trifluoroacetate in trifluoroacetic acid. After cyclization was achieved the resin and side chain protecting groups were cleaved with liquid HF in the presence of dimethylsulfide and anisole. The des-¹Lys-h-amylin was purified by preparative reversed-phase HPLC. The peptide was found to be homogeneous by analytical HPLC and capillary electrophoresis and the structure confirmed by amino acid analysis and sequence analysis. The product gave the desired mass ion. FAB mass spec: (M+H)⁺=3,775.

Example 5

Preparation of ¹Ala-h-Amylin

[0045] Solid phase synthesis of ¹Ala-h-amylin using methylbenzhydrylamine anchor-bond resin and N^a-Boc/benzyl-side chain protection was carried out by standard peptide synthesis methods. The 2,7-[disulfide] amylin-MBHA-resin was obtained by treatment of Acm-protected cysteines with thallium (III) trifluoroacetate in trifluoroacetic acid. After cyclization was achieved the resin and side chain protecting groups were cleaved with liquid HF in the presence of dimethylsulfide and anisole. The ¹Ala-h-amylin was purified by preparative reversed-phase HPLC. The peptide was found to be homogeneous by analytical HPLC and capillary electrophoresis and the structure confirmed by amino acid analysis and sequence analysis. The product gave the desired mass ion. FAB mass spec: (M+H)⁺=3,847.

Example 6

Preparation of ¹Ser-h-Amylin

[0046] Solid phase synthesis of ¹Ser-h-amylin using methylbenzhydrylamine anchor-bond resin and N^a-Boc/benzyl-side chain protection was carried out by standard peptide synthesis methods. The 2,7-[disulfide]amylin-MBHA-resin was obtained by treatment of Acm-protected cysteines with thallium (III) trifluoroacetate in trifluoroacetic acid. After cyclization was achieved the resin and side chain protecting groups were cleaved with liquid HF in the presence of dimethylsulfide and anisole. The ¹Ser-h-amylin was purified by preparative reversed-phase HPLC. The peptide was found to be homogeneous by analytical HPLC and capillary electrophoresis and the structure confirmed by amino acid analysis and sequence analysis. The product gave the desired mass ion. FAB mass spec: (M+H)⁺=3,863.

Example 7

Preparation of ²⁹Pro-h-Amylin

[0047] Solid phase synthesis of this analogue of human amylin using methylbenzhydrylamine anchor-bond resin and N^a-Boc/benzyl-side chain protection was carried out by standard peptide synthesis methods. The 2,7-(disulfide) amylin-MBHA-resin was obtained by treatment of Acm-protected cysteines with thallium (III) trifluoroacetate in trifluoroacetic acid. After cyclization was achieved the resin and side chain protecting groups were cleaved with liquid HF in the presence of dimethylsulfide and anisole. The ²⁹Pro-h-amylin was purified by preparative HPLC. The peptide was found to be homogeneous by analytical HPLC and capillary electrophoresis and the structure confirmed by amino acid analysis and sequence analysis. The product gave the desired mass ion. FAB mass spec: (M+H)⁺=3916.

Example 8

Preparation of ^{25,28}Pro-h-Amylin

[0048] Solid phase synthesis of ^{25,28}Pro-h-amylin using methylbenzhydrylamine anchor-bond resin and Na-Boc/benzylside chain protection was carried out by standard peptide synthesis methods. The 2,7-[disulfide] amylin-MBHA-resin was obtained by treatment of Acm-protected cysteines with thallium (III) trifluoroacetate in trifluoroacetic acid. After cyclization was achieved the resin and side chain protecting groups were cleaved with liquid HF in the presence of dimethylsulfide and anisole. The ^{25,28}Pro-h-amylin was purified by preparative reversed-phase HPLC. The peptide was found to be homogeneous by analytical HPLC and capillary electrophoresis and the structure confirmed by amino acid analysis and sequence analysis. The product gave the desired mass ion. FAB mass spec: (M+H)⁺=3,939.

Example 9Preparation of des-¹Lys^{25,28}Pro-h-Amylin

[0049] Solid phase synthesis of des-¹Lys^{25,28}Pro-h-amylin using methylbenzhydrylamine anchor-bond resin and N^a-Boc/benzylside chain protection was carried out by standard peptide synthesis methods. The 2,7-[disulfide] amylin-MBHA-resin was obtained by treatment of Acm-protected cysteines with thallium (III) trifluoroacetate in trifluoroacetic acid. After cyclization was achieved the resin and side chain protecting groups were cleaved with liquid HF in the presence of dimethylsulfide and anisole. The des-¹Lys^{25,28}Pro-h-amylin was purified by preparative reversed-phase HPLC. The peptide was found to be homogeneous by analytical HPLC and capillary electrophoresis and the structure confirmed by amino acid analysis and sequence analysis. The product gave the desired mass ion. FAB mass spec: (M+H)⁺=3,811.

Example 10Preparation of ¹⁸Arg^{25,28}Pro-h-Amylin

[0050] Solid phase synthesis of ¹⁸Arg^{25,28}Pro-h-amylin using methylbenzhydrylamine anchor-bond resin and N^a-Boc/benzylside chain protection was carried out by standard peptide synthesis methods. The 2,7-[disulfide] amylin-MBHA-resin was obtained by treatment of Acm-protected cysteines with thallium (III) trifluoroacetate in trifluoroacetic acid. After cyclization was achieved the resin and side chain protecting groups were cleaved with liquid HF in the presence of dimethylsulfide and anisole. The ¹⁸Arg^{25,28}Pro-h-amylin was purified by preparative reversed-phase HPLC. The peptide was found to be homogeneous by analytical HPLC and capillary electrophoresis and the structure confirmed by amino acid analysis and sequence analysis. The product gave the desired mass ion. FAB mass spec: (M+H)⁺=3,959.

Example 11Preparation of des-¹Lys¹⁸Arg^{25,28}Pro-h-Amylin

[0051] Solid phase synthesis of des-¹Lys¹⁸Arg^{25,28}Pro-h-amylin using methylbenzhydrylamine anchor-bond resin and N^a-Boc/benzyl-side chain protection was carried out by standard peptide synthesis methods. The 2,7-[disulfide] amylin-MBHA-resin was obtained by treatment of Acm-protected cysteines with thallium (III) trifluoroacetate in trifluoroacetic acid. After cyclization was achieved the resin and side chain protecting groups were cleaved with liquid HF in the presence of dimethylsulfide and anisole. The des-¹Lys¹⁸Arg^{25,28}Pro-h-amylin was purified by preparative reversed-phase HPLC. The peptide was found to be homogeneous by analytical HPLC and capillary electrophoresis and the structure confirmed by amino acid analysis and sequence analysis. The product gave the desired mass ion. FAB mass spec: (M+H)⁺=3,832.

Example 12Preparation of ¹⁸Arg^{25,28,29}Pro-h-Amylin

[0052] Solid phase synthesis of ¹⁸Arg^{25,28,29}Pro-h-amylin using methylbenzhydrylamine anchor-bond resin and N^a-Boc/benzylside chain protection was carried out by standard peptide synthesis methods. The 2,7-[disulfide] amylin-MBHA-resin was obtained by treatment of Acm-protected cysteines with thallium (III) trifluoroacetate in trifluoroacetic acid. After cyclization was achieved the resin and side chain protecting groups were cleaved with liquid HF in the presence of dimethylsulfide and anisole. The ¹⁸Arg^{25,28,29}Pro-h-amylin was purified by preparative reversed-phase HPLC. The peptide was found to be homogeneous by analytical HPLC and capillary electrophoresis and the structure confirmed by amino acid analysis and sequence analysis. The product gave the desired mass ion. FAB mass spec: (M+H)⁺=3,971.

Example 13Preparation of des-¹Lys¹⁸Arg^{25,28,29}Pro-h-Amylin

[0053] Solid phase synthesis of des-¹Lys¹⁸Arg^{25,28,29}Pro-h-amylin using methylbenzhydrylamine anchor-bond resin and N^a-Boc/benzyl-side chain protection was carried out by standard peptide synthesis methods. The 2,7-[disulfide] amylin-MBHA-resin was obtained by treatment of Acm-protected cysteines with thallium (III) trifluoroacetate in trifluoro-

oacetic acid. After cyclization was achieved the resin and side chain protecting groups were cleaved with liquid HF in the presence of dimethylsulfide and anisole. The des-¹Lys¹⁸Arg^{25,28,29}Pro-h-amylin was purified by preparative reversed-phase HPLC. The peptide was found to be homogeneous by analytical HPLC and capillary electrophoresis and the structure confirmed by amino acid analysis and sequence analysis. The product gave the desired mass ion. FAB mass spec: (M+H)⁺=3,843.

Example 14

Preparation of ^{25,28,29}Pro-h-Amylin

[0054] Solid phase synthesis of ^{25,28,29}Pro-h-amylin using methylbenzhydrylamine anchor-bond resin and N^a-Boc/benzylside chain protection was carried out by standard peptide synthesis methods. The 2,7-[disulfide] amylin-MBHA-resin was obtained by treatment of AcM-protected cysteines with thallium (III) trifluoroacetate in trifluoroacetic acid. After cyclization was achieved the resin and side chain protecting groups were cleaved with liquid HF in the presence of dimethylsulfide and anisole. The ^{25,28,29}Pro-h-amylin was purified by preparative reversed-phase HPLC. The peptide was found to be homogeneous by analytical HPLC and capillary electrophoresis and the structure confirmed by amino acid analysis and sequence analysis. The product gave the desired mass ion. FAB mass spec: (M+H)⁺=3,949.

Example 15

Preparation of des-¹Lys^{25,28,29}Pro-h-Amylin

[0055] Solid phase synthesis of des-¹Lys^{25,28,29}Pro-h-amylin using methylbenzhydrylamine anchor-bond resin and N^a-Boc/benzyl-side chain protection was carried out by standard peptide synthesis methods. The 2,7-[disulfide] amylin-MBHA-resin was obtained by treatment of AcM-protected cysteines with thallium (III) trifluoroacetate in trifluoroacetic acid. After cyclization was achieved the resin and side chain protecting groups were cleaved with liquid HF in the presence of dimethylsulfide and anisole. The des-¹Lys^{25,28,29}Pro-h-amylin was purified by preparative reversed-phase HPLC. The peptide was found to be homogeneous by analytical HPLC and capillary electrophoresis and the structure confirmed by amino acid analysis and sequence analysis. The product gave the desired mass ion. FAB mass spec: (M+H)⁺=3,823.

Example 16

Preparation of des-¹Lys²⁵Pro²⁶Val^{28,29}Pro-h-Amylin

[0056] Solid phase synthesis of this h-amylin analogue using methylbenzhydrylamine anchor-bond resin and N^a-Boc/benzylside chain protection is carried out by standard peptide synthesis methods, and the 2,7-[disulfide] amylin-MBHA-resin obtained by treatment with thallium (III) trifluoroacetate in trifluoroacetic acid. After cyclization is achieved the resin and side chain protecting groups are cleaved with liquid HF in the presence of dimethylsulfide and anisole. The des-¹Lys²⁵Pro²⁶Val^{28,29}Pro-h-amylin is then purified by preparative HPLC.

Example 17

Preparation of [(D)-¹¹Arg]-Amylin

[0057] Solid phase synthesis of this amylin analogue using methylbenzhydrylamine anchor-bond resin and N^a-Boc/benzylside chain protection is carried out by standard peptide synthesis methods. (D)-¹¹Arg is introduced with Boc-(D)-¹¹Arg(Mtr)-OH. The 2,7-[disulfide] amylin-MBHA-resin, obtained by treatment with thallium (III) trifluoroacetate in trifluoroacetic acid, is cyclized and the resin and side chain protecting groups are cleaved with liquid HF in the presence of dimethylsulfide and anisole. The [(D)-¹¹Arg]-amylin is then purified by preparative HPLC.

Example 18

Receptor Binding Assay

[0058] Evaluation of the binding of compounds of the invention to amylin receptors was carried out as follows. [¹²⁵I]-rat amylin (Bolton-Hunter labeled at the N-terminal lysine) was purchased from Amersham Corporation (Arlington Heights, IL). Specific activities at time of use ranged from 1950 to 2000 Ci/mmol. Unlabeled peptides were obtained

from BACHEM Inc. (Torrance, CA) and Peninsula Laboratories (Belmont, CA).

[0059] Male Sprague-Dawley rats (200-250) grams were sacrificed by decapitation. Brains were removed to cold phosphate-buffered saline (PBS). From the ventral surface, cuts were made rostral to the hypothalamus, bounded laterally by the olfactory tracts and extending at a 45° angle medially from these tracts. This basal forebrain tissue, containing the nucleus accumbens and surrounding regions, was weighed and homogenized in icecold 20 mM HEPES buffer (20 mM HEPES acid, pH adjusted to 7.4 with NaOH at 23°C). Membranes were washed three times in fresh buffer by centrifugation for 15 minutes at 48,000 x g. The final membrane pellet was resuspended in 20 mM HEPES buffer containing 0.2 mM phenylmethylsulfonyl fluoride (PMSF).

[0060] To measure ¹²⁵I-amylin binding, membranes from 4 mg original wet weight of tissue were incubated with ¹²⁵I-amylin at 12-16 pM in 20 mM HEPES buffer containing 0.5 mg/ml bacitracin, 0.5 mg/ml bovine serum albumin, and 0.2 mM PMSF. Solutions were incubated for 60 minutes at 23°C. Incubations were terminated by filtration through GF/B glass fiber filters (Whatman Inc., Clifton, NJ) which had been presoaked for 4 hours in 0.3% polyethyleneimine in order to reduce nonspecific binding of radiolabeled peptides. Filters were washed immediately before filtration with 5 ml cold PBS, and immediately after filtration with 15 ml cold PBS. Filters were removed and radioactivity assessed in a gamma-counter at a counting efficiency of 77%. Competition curves were generated by measuring binding in the presence of 10⁻¹² to 10⁻⁶ M unlabeled test compound and were analyzed by nonlinear regression using a 4-parameter logistic equation (Inplot program; GraphPAD Software, San Diego).

[0061] In this assay, purified human amylin binds to its receptor at a measured IC₅₀ of about 50 pM. Results for test compounds of the invention are set forth in Table I, showing that each of the compounds has significant receptor binding activity.

Example 19

Soleus Muscle Assay

[0062] Evaluation of the amylin agonist activity of compounds of the invention was carried out using the soleus muscle assay as follows. Male Harlan Sprague-Dawley rats of approximately 200g mass were used in order to maintain mass of the split soleus muscle less than 40mg. The animals were fasted for 4 hours prior to sacrifice by decapitation. The skin was stripped from the lower limb which was then pinned out on corkboard. The tendo achilles was cut just above os calcis and m. gastrocnemius reflected out from the posterior aspect of the tibia. M. soleus, a small 15-20mm long, 0.5mm thick flat muscle on the bone surface of m. gastrocnemius was then stripped clear and the perimysium cleaned off using fine scissors and forceps. M. soleus was then split into equal parts using a blade passed antero-posteriorly through the belly of the muscle to obtain a total of 4 muscle strips from each animal. After dissecting the muscle from the animal, it was kept for a short period in physiological saline. It was not necessary that the muscle be held under tension as this had no demonstrable effects on radioglucose incorporation into glycogen.

[0063] Muscles were added to 50mL Erlenmeyer flasks containing 10mL of a pregassed Krebs-Ringer bicarbonate buffer containing (each liter) NaCl 118.5 mmol (6.93g), KCl 5.94 mmol (443mg), CaCl₂ 2.54 mmol (282mg), MgSO₄ 1.19 mmol (143mg), KH₂PO₄ 1.19 mmol (162mg), NaHCO₃ 25 mmol (2.1g), 5.5mmol glucose (lg) and recombinant human insulin (Humulin-R, Eli Lilly, IN) and the test compound, as detailed below. pH at 37°C was verified as being between 7.1 and 7.4. Muscles were assigned to different flasks so that the 4 muscle pieces from each animal were evenly distributed among the different assay conditions. The incubation media were gassed by gently blowing Carbogen (95% O₂, 5% CO₂) over the surface while being continuously agitated at 37°C in an oscillating water bath. After a half-hour "preincubation" period, 0.5μCi of U-¹⁴C-glucose was added to each flask which was incubated for a further 60 minutes. Each muscle piece was then rapidly removed, blotted and frozen in liquid N₂, weighed and stored for subsequent determination of ¹⁴C-glycogen.

[0064] ¹⁴C-glycogen determination was performed in a 7mL scintillation vial. Each frozen muscle specimen was placed in a vial and digested in 1mL 60% potassium hydroxide at 70°C for 45 minutes under continuous agitation. Dissolved glycogen was precipitated out onto the vial by the addition of 3mL absolute ethanol and overnight cooling at -20°C. The supernatant was gently aspirated, the glycogen washed again with ethanol, aspirated and the precipitate dried under vacuum. All ethanol is evaporated to avoid quenching during scintillation counting. The remaining glycogen was redissolved in 1mL water and 4mL scintillation fluid and counted for ¹⁴C.

[0065] The rate of glucose incorporation into glycogen (expressed in μmol/g/hr) was obtained from the specific activity of ¹⁴C-glucose in the 5.5mM glucose of the incubation medium, and the total ¹⁴C counts remaining in the glycogen extracted from each muscle. Dose/response curves were fitted to a 4-parameter logistic model using a least-squares iterative routine (ALLFIT, v2.7, NIH, MD) to derive EC₅₀'s. Since EC₅₀ is log-normally distributed, it is expressed ± standard error of the logarithm. Pairwise comparisons were performed using t-test based routines of SYSTAT (Wilkinson, "SYSTAT: the system for statistics," SYSTAT Inc., Evanston IL (1989)).

[0066] Dose response curves were generated with muscles added to media containing 7.1nM (1000μU/mL) insulin

EP 1 162 207 A1

and each test compound added at final (nominal) concentrations of 0, 1, 3, 10, 30, 100, 300 and 1000nM. Each assay also contained internal positive controls consisting of a single batch of archived rat amylin, lyophilized and stored at -70°C.

[0067] Human amylin is a known hyperglycemic peptide, and EC₅₀ measurements of amylin preparations in the soleus muscle assay range typically from about 1-10 nM, although some commercial preparations which are less than 90% pure have higher EC₅₀'s due to the presence of contaminants that result in a lower measured activity. Results for test compounds are set forth in Table I, showing that each of the compounds has amylin activity.

TABLE I

		Receptor Binding Assay IC ₅₀ (pM)	Soleus Muscle Assay EC ₅₀ (nM)
1)	28Pro-h-Amylin	15.0	2.64
2)	25Pro ²⁶ Val ^{28,29} Pro-h-Amylin	18.0	4.68
3)	2,7Cyclo-[² Asp, ⁷ Lys]-Amylin	310.0	6.62
4)	2-37h-Amylin	236.0	1.63
5)	¹ Ala-h-Amylin	148.0	12.78
6)	¹ Ser-h-Amylin	33.0	8.70
7)	²⁹ Pro-h-Amylin	64.0	3.75
8)	25,28Pro-h-Amylin	26.0	13.20
9)	des- ¹ Lys ^{25,28} Pro-h-Amylin	85.0	7.70
10)	¹⁸ Arg ^{25,28} Pro-h-Amylin	32.0	2.83
11)	des- ¹ Lys ¹⁸ Arg ^{25,28} Pro-h-Amylin	82.0	3.77
12)	¹⁸ Arg ^{25,28,29} Pro-h-Amylin	21.0	1.25
13)	des- ¹ Lys ¹⁸ Arg ^{25,28,29} Pro-h-Amylin	21.0	1.86
14)	25,28,29Pro-h-Amylin	10.0	3.71
15)	des- ¹ Lys ^{25,28,29} Pro-h-Amylin	14.0	4.15



TABLE II

	<u>A₁</u>	<u>B₁</u>	<u>C₁</u>	<u>D₁</u>	<u>E₁</u>	<u>F₁</u>	<u>G₁</u>	<u>H₁</u>	<u>I₁</u>	<u>J₁</u>	<u>K₁</u>	<u>L₁</u>	<u>M₁</u>	<u>Z</u>
18)	Lys	Ala	Val	His	Ser	Ser	Asn	Leu	Pro	Val	Pro	Pro	Asn	-NH ₂
19)	Lys	Ala	Val	His	Ser	Ser	Asn	Leu	Pro	Val	Pro	Ser	Asn	-NH ₂
20)	Hydrogen	Ala	Val	His	Ser	Ser	Asn	Leu	Pro	Val	Pro	Ser	Asn	-NH ₂
21)	Lys	Ala	Val	Arg	Ser	Ser	Asn	Leu	Pro	Val	Pro	Ser	Asn	-NH ₂
22)	Lys	Ala	Val	Arg	Ser	Ser	Asn	Leu	Pro	Ile	Pro	Pro	Asn	-NH ₂
23)	Lys	Ala	Val	Arg	Ser	Ser	Asn	Leu	Pro	Ile	Pro	Ser	Asn	-NH ₂
24)	Lys	Ala	Ile	His	Ser	Ser	Asn	Leu	Pro	Ile	Pro	Pro	Asn	-NH ₂
25)	Lys	Ala	Ile	His	Ser	Ser	Asn	Phe	Pro	Ile	Pro	Pro	Asn	-NH ₂
26)	Hydrogen	Ala	Ile	His	Ser	Ser	Asn	Leu	Pro	Ile	Pro	Pro	Asn	-NH ₂
27)	Lys	Ala	Ile	Arg	Ser	Ser	Asn	Leu	Ala	Ile	Ser	Ser	Asn	-NH ₂
28)	Lys	Ala	Ile	Arg	Ser	Ser	Asn	Leu	Ala	Val	Ser	Pro	Asn	-NH ₂
29)	Lys	Ala	Ile	Arg	Ser	Ser	Asn	Leu	Pro	Val	Pro	Pro	Asn	-NH ₂
30)	Lys	Thr	Val	His	Ser	Ser	His	Leu	Ala	Ala	Leu	Pro	Asp	-NH ₂
31)	Lys	Thr	Val	His	Ser	Ser	His	Leu	Ala	Ala	Ser	Pro	Asp	-NH ₂
32)	Hydrogen	Thr	Val	His	Ser	Ser	His	Leu	Ala	Ala	Pro	Ser	Asp	-NH ₂
33)	Lys	Thr	Val	Arg	Ser	Ser	His	Leu	Ala	Ala	Ser	Pro	Asp	-NH ₂
34)	Lys	Thr	Val	Arg	Ser	Ser	His	Leu	Ala	Ile	Pro	Pro	Asp	-NH ₂
35)	Lys	Thr	Val	Arg	Ser	Ser	His	Leu	Pro	Ala	Pro	Pro	Asp	-NH ₂

Annex to the application documents - subsequently filed sequences filing

[0068]

SEQUENCE LISTING

<110> AMYLIN PHARMACEUTICALS, INC.

<120> NOVEL AMYLIN AGONIST PEPTIDES AND USES THEREFOR

<130> N66914B TJD

<140> 01114132.2

<141> 1992-11-19

<150> US 07/794,266

<151> 1991-11-19

<160> 67

<170> PatentIn version 3.0

<210> 1

<211> 37

<212> PRT

<213> Homo sapiens

<400> 1

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 2

<211> 37

<212> PRT

<213> Felis catus

<400> 2

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Ile Arg Ser Ser Asn Asn Leu Gly Ala Ile Leu Ser Pro Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 3
<211> 37
<212> PRT
<213> Canis familiaris

<400> 3
Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15
Val Arg Thr Ser Asn Asn Leu Gly Ala Ile Leu Ser Pro Thr Asn Val
20 25 30
Gly Ser Asn Thr Tyr
35

<210> 4
<211> 37
<212> PRT
<213> Rattus sp.

<400> 4
Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15
Val Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val
20 25 30
Gly Ser Asn Thr Tyr
35

<210> 5
<211> 37
<212> PRT
<213> Mus sp.

<400> 5
Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15
Val Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val
20 25 30
Gly Ser Asn Thr Tyr
35

<210> 6

<211> 37
 <212> PRT
 <213> Mesocricetus sp.

<400> 6
 Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Val His Ser Asn Asn Leu Gly Pro Val Leu Ser Pro Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 7
 <211> 37
 <212> PRT
 <213> Cavia sp.

<400> 7
 Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Thr Asn Phe Leu
 1 5 10 15
 Val Arg Ser Ser His Asn Leu Gly Ala Ala Leu Leu Pro Thr Asp Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 8
 <211> 37
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 amylin peptide

<220>
 <221> MOD_RES
 <222> (1)
 <223> K, S, or A

<220>
 <221> MOD_RES
 <222> (2)
 <223> Any amino acid

<220>

<221> MOD_RES

<222> (7)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (13)

<223> A, S, or T

<220>

<221> MOD_RES

<222> (17)

<223> V, L, or I

<220>

<221> MOD_RES

<222> (18)

<223> H or R

<220>

<221> MOD_RES

<222> (19)

<223> S or T

<220>

<221> MOD_RES

<222> (20)

<223> S, T, Q, or N

<220>

<221> MOD_RES

<222> (21)

<223> N, Q, or H

<220>

<221> MOD_RES

<222> (23)

<223> F, L, or Y

<220>

<221> MOD_RES

<222> (25)

<223> A or P

<220>

<221> MOD_RES

<222> (26)

<223> I, V, A, or L

<220>

<221> MOD_RES

<222> (28)

<223> S, P, L, I, or T

<220>

<221> MOD_RES

<222> (29)

<223> S, P, or T

<220>

<221> MOD_RES

<222> (31)

<223> N, D, or Q

<400> 8

Xaa	Xaa	Asn	Thr	Ala	Thr	Xaa	Ala	Thr	Gln	Arg	Leu	Xaa	Asn	Phe	Leu
1				5				10					15		
Xaa	Xaa	Xaa	Xaa	Xaa	Asn	Xaa	Gly	Xaa	Xaa	Leu	Xaa	Xaa	Thr	Xaa	Val
		20					25						30		
Gly	Ser	Asn	Thr	Tyr											
		35													

<210> 9

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic amylin peptide

<220>

<221> MOD_RES

<222> (2)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (7)

<223> Any amino acid

<400> 9

Lys Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 10

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 amylin peptide

<220>

<221> MOD_RES

<222> (2)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (7)

<223> Any amino acid

<400> 10

Lys Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Ile Arg Ser Ser Asn Asn Leu Gly Ala Ile Leu Ser Pro Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 11

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 amylin peptide

<220>

<221> MOD_RES
 <222> (2)
 <223> Any amino acid

<220>
 <221> MOD_RES
 <222> (7)
 <223> Any amino acid

<400> 11
 Lys Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Val Arg Thr Ser Asn Asn Leu Gly Ala Ile Leu Ser Pro Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 12
 <211> 37
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 amylin peptide

<220>
 <221> MOD_RES
 <222> (2)
 <223> Any amino acid

<220>
 <221> MOD_RES
 <222> (7)
 <223> Any amino acid

<400> 12
 Lys Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Val Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 13

<211> 37
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 amylin peptide

<220>
 <221> MOD_RES
 <222> (2)
 <223> Any amino acid

<220>
 <221> MOD_RES
 <222> (7)
 <223> Any amino acid

<400> 13
 Lys Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Val His Ser Asn Asn Asn Leu Gly Pro Val Leu Ser Pro Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 14
 <211> 37
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 amylin peptide

<220>
 <221> MOD_RES
 <222> (2)
 <223> Any amino acid

<220>
 <221> MOD_RES
 <222> (7)
 <223> Any amino acid

<400> 14

EP 1 162 207 A1

Lys Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Thr Asn Phe Leu
 1 5 10 15
 Val Arg Ser Ser His Asn Leu Gly Ala Ala Leu Leu Pro Thr Asp Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 15
 <211> 37
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 amylin peptide

<400> 15
 Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Val Arg Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Ser Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 16
 <211> 36
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 amylin peptide

<400> 16
 Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val
 1 5 10 15
 His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val Gly
 20 25 30
 Ser Asn Thr Tyr
 35

<210> 17
 <211> 37
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<400> 17

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Pro Ser Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 18

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<400> 18

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Val His Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Pro Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 19

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<400> 19

Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val
 1 5 10 15
 Arg Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Ser Thr Asn Val Gly
 20 25 30
 Ser Asn Thr Tyr
 35

EP 1 162 207 A1

<210> 20
 <211> 37
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 amylin peptide

<400> 20
 Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Val His Ser Ser Asn Asn Phe Gly Pro Val Leu Pro Pro Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 21
 <211> 37
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 amylin peptide

<400> 21
 Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Val Arg Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Pro Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 22
 <211> 36
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 amylin peptide

<400> 22
 Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val
 1 5 10 15

Arg Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Pro Thr Asn Val Gly
 20 25 30

Ser Asn Thr Tyr
 35

<210> 23

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 amylin peptide

<400> 23

Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val
 1 5 10 15

His Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Pro Thr Asn Val Gly
 20 25 30

Ser Asn Thr Tyr
 35

<210> 24

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 amylin peptide

<400> 24

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Pro Val Leu Pro Ser Thr Asn Val
 20 25 30

Gly Ser Asn Thr Tyr
 35

<210> 25

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<400> 25

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15
Val His Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val
20 25 30
Gly Ser Asn Thr Tyr
35

<210> 26

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<400> 26

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15
Val His Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Ser Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 27

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<400> 27

Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val
1 5 10 15
His Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Ser Thr Asn Val Gly
20 25 30
Ser Asn Thr Tyr
35

<210> 28
 <211> 37
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 amylin peptide

<400> 28
 Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Val Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Ser Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 29
 <211> 37
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 amylin peptide

<400> 29
 Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Val Arg Ser Ser Asn Asn Leu Gly Pro Ile Leu Pro Pro Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 30
 <211> 37
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 amylin peptide

<400> 30

EP 1 162 207 A1

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Val Arg Ser Ser Asn Asn Leu Gly Pro Ile Leu Pro Ser Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 31

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 amylin peptide

<400> 31

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Ile His Ser Ser Asn Asn Leu Gly Pro Ile Leu Pro Pro Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 32

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 amylin peptide

<400> 32

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Ile His Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Pro Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 33

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<400> 33

Cys	Asn	Thr	Ala	Thr	Cys	Ala	Thr	Gln	Arg	Leu	Ala	Asn	Phe	Leu	Ile
1				5				10					15		
His	Ser	Ser	Asn	Asn	Leu	Gly	Pro	Ile	Leu	Pro	Pro	Thr	Asn	Val	Gly
			20				25						30		
Ser	Asn	Thr	Tyr												
			35												

<210> 34

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<400> 34

Lys	Cys	Asn	Thr	Ala	Thr	Cys	Ala	Thr	Gln	Arg	Leu	Ala	Asn	Phe	Leu
1				5					10					15	
Ile	Arg	Ser	Ser	Asn	Asn	Leu	Gly	Ala	Ile	Leu	Ser	Ser	Thr	Asn	Val
			20				25						30		
Gly	Ser	Asn	Thr	Tyr											
			35												

<210> 35

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<400> 35

Lys	Cys	Asn	Thr	Ala	Thr	Cys	Ala	Thr	Gln	Arg	Leu	Ala	Asn	Phe	Leu
1				5					10					15	

EP 1 162 207 A1

Ile Arg Ser Ser Asn Asn Leu Gly Ala Val Leu Ser Pro Thr Asn Val
 20 25 30

Gly Ser Asn Thr Tyr
 35

<210> 36

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 amylin peptide

<400> 36

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15

Ile Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val
 20 25 30

Gly Ser Asn Thr Tyr
 35

<210> 37

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 amylin peptide

<400> 37

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Thr Asn Phe Leu
 1 5 10 15

Val His Ser Ser His Asn Leu Gly Ala Ala Leu Leu Pro Thr Asp Val
 20 25 30

Gly Ser Asn Thr Tyr
 35

<210> 38

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<400> 38

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Thr Asn Phe Leu
1 5 10 15
Val His Ser Ser His Asn Leu Gly Ala Ala Leu Ser Pro Thr Asp Val
20 25 30
Gly Ser Asn Thr Tyr
35

<210> 39

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<400> 39

Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Thr Asn Phe Leu Val
1 5 10 15
His Ser Ser His Asn Leu Gly Ala Ala Leu Pro Ser Thr Asp Val Gly
20 25 30
Ser Asn Thr Tyr
35

<210> 40

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<400> 40

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Thr Asn Phe Leu
1 5 10 15
Val Arg Ser Ser His Asn Phe Gly Ala Ala Leu Ser Pro Thr Asp Val
20 25 30
Gly Ser Asn Thr Tyr
35

<210> 41
 <211> 37
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 amylin peptide

<400> 41
 Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Thr Asn Phe Leu
 1 5 10 15
 Val Arg Ser Ser His Asn Phe Gly Ala Ile Leu Pro Pro Thr Asp Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 42
 <211> 37
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 amylin peptide

<400> 42
 Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Thr Asn Phe Leu
 1 5 10 15
 Val Arg Ser Ser His Asn Phe Gly Pro Ala Leu Pro Pro Thr Asp Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 43
 <211> 37
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 amylin peptide

<400> 43

Lys Asp Asn Thr Ala Thr Lys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 44

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<400> 44

Ala Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 45

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<400> 45

Ser Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 46

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<400> 46

Lys	Cys	Asn	Thr	Ala	Thr	Cys	Ala	Thr	Gln	Arg	Leu	Ala	Asn	Phe	Leu
1				5				10					15		
Val	His	Ser	Ser	Asn	Asn	Phe	Gly	Ala	Ile	Leu	Ser	Pro	Thr	Asn	Val
			20				25						30		
Gly	Ser	Asn	Thr	Tyr											
			35												

<210> 47

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<400> 47

Lys	Cys	Asn	Thr	Ala	Thr	Cys	Ala	Thr	Gln	Arg	Leu	Ala	Asn	Phe	Leu
1				5				10					15		
Val	His	Ser	Ser	Asn	Asn	Phe	Gly	Pro	Ile	Leu	Pro	Ser	Thr	Asn	Val
			20				25						30		
Gly	Ser	Asn	Thr	Tyr											
			35												

<210> 48

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<400> 48

Cys	Asn	Thr	Ala	Thr	Cys	Ala	Thr	Gln	Arg	Leu	Ala	Asn	Phe	Leu	Val
1				5				10				15			
His	Ser	Ser	Asn	Asn	Phe	Gly	Pro	Ile	Leu	Pro	Ser	Thr	Asn	Val	Gly

5 Gly Ser Asn Thr Tyr 20 25 30
35

10 <210> 51
<211> 37
<212> PRT
<213> Artificial Sequence

15 <220>
<223> Description of Artificial Sequence: Synthetic
amylin peptide

20 <220>
<221> MOD_RES
<222> (2)
<223> Any amino acid

25 <220>
<221> MOD_RES
<222> (7)
<223> Any amino acid

30 <400> 51
Lys Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15
35 Val His Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Ser Thr Asn Val
20 25 30
Gly Ser Asn Thr Tyr
35

40 <210> 52
<211> 36
<212> PRT
<213> Artificial Sequence

45 <220>
<223> Description of Artificial Sequence: Synthetic
amylin peptide

50 <220>
<221> MOD_RES
55 <222> (1)
<223> Any amino acid

<220>

<221> MOD_RES

<222> (6)

<223> Any amino acid

<400> 52

Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Ala Asn Phe Leu Val
 1 5 10 15
 His Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Ser Thr Asn Val Gly
 20 25 30
 Ser Asn Thr Tyr
 35

<210> 53

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic amylin peptide

<220>

<221> MOD_RES

<222> (2)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (7)

<223> Any amino acid

<400> 53

Lys Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Val Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Ser Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 54

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<220>

<221> MOD_RES

<222> (2)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (7)

<223> Any amino acid

<400> 54

Lys	Xaa	Asn	Thr	Ala	Thr	Xaa	Ala	Thr	Gln	Arg	Leu	Ala	Asn	Phe	Leu
1				5				10					15		
Val	Arg	Ser	Ser	Asn	Asn	Leu	Gly	Pro	Ile	Leu	Pro	Pro	Thr	Asn	Val
			20				25						30		
Gly	Ser	Asn	Thr	Tyr											
			35												

<210> 55

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<220>

<221> MOD_RES

<222> (2)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (7)

<223> Any amino acid

<400> 55

Lys	Xaa	Asn	Thr	Ala	Thr	Xaa	Ala	Thr	Gln	Arg	Leu	Ala	Asn	Phe	Leu
1				5				10					15		
Val	Arg	Ser	Ser	Asn	Asn	Leu	Gly	Pro	Ile	Leu	Pro	Ser	Thr	Asn	Val

20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 56
 <211> 37
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 amylin peptide

<220>
 <221> MOD_RES
 <222> (2)
 <223> Any amino acid

<220>
 <221> MOD_RES
 <222> (7)
 <223> Any amino acid

<400> 56
 Lys Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Ile His Ser Ser Asn Asn Leu Gly Pro Ile Leu Pro Pro Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 57
 <211> 37
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 amylin peptide

<220>
 <221> MOD_RES
 <222> (2)
 <223> Any amino acid

<220>

<221> MOD_RES

<222> (7)

<223> Any amino acid

<400> 57

Lys Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Ile His Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Pro Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 58

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 amylin peptide

<220>

<221> MOD_RES

<222> (1)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (6)

<223> Any amino acid

<400> 58

Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Ala Asn Phe Leu Ile
 1 5 10 15
 His Ser Ser Asn Asn Leu Gly Pro Ile Leu Pro Pro Thr Asn Val Gly
 20 25 30
 Ser Asn Thr Tyr
 35

<210> 59

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<220>

<221> MOD_RES

<222> (2)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (7)

<223> Any amino acid

<400> 59

Lys	Xaa	Asn	Thr	Ala	Thr	Xaa	Ala	Thr	Gln	Arg	Leu	Ala	Asn	Phe	Leu
1				5				10					15		
Ile	Arg	Ser	Ser	Asn	Asn	Leu	Gly	Ala	Ile	Leu	Ser	Ser	Thr	Asn	Val
		20				25							30		
Gly	Ser	Asn	Thr	Tyr											
		35													

<210> 60

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<220>

<221> MOD_RES

<222> (2)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (7)

<223> Any amino acid

<400> 60

Lys	Xaa	Asn	Thr	Ala	Thr	Xaa	Ala	Thr	Gln	Arg	Leu	Ala	Asn	Phe	Leu
1				5				10					15		
Ile	Arg	Ser	Ser	Asn	Asn	Leu	Gly	Ala	Val	Leu	Ser	Pro	Thr	Asn	Val

20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 61
 <211> 37
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 amylin peptide

<220>
 <221> MOD_RES
 <222> (2)
 <223> Any amino acid

<220>
 <221> MOD_RES
 <222> (7)
 <223> Any amino acid

<400> 61
 Lys Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15
 Ile Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 62
 <211> 37
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 amylin peptide

<220>
 <221> MOD_RES
 <222> (2)
 <223> Any amino acid

<220>

<221> MOD_RES

<222> (7)

<223> Any amino acid

<400> 62

Lys Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Thr Asn Phe Leu
 1 5 10 15
 Val His Ser Ser His Asn Leu Gly Ala Ala Leu Leu Pro Thr Asp Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 63

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic amylin peptide

<220>

<221> MOD_RES

<222> (2)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (7)

<223> Any amino acid

<400> 63

Lys Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Thr Asn Phe Leu
 1 5 10 15
 Val His Ser Ser His Asn Leu Gly Ala Ala Leu Ser Pro Thr Asp Val
 20 25 30
 Gly Ser Asn Thr Tyr
 35

<210> 64

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<220>

<221> MOD_RES

<222> (1)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (6)

<223> Any amino acid

<400> 64

Xaa	Asn	Thr	Ala	Thr	Xaa	Ala	Thr	Gln	Arg	Leu	Thr	Asn	Phe	Leu	Val
1				5				10					15		
His	Ser	Ser	His	Asn	Leu	Gly	Ala	Ala	Leu	Pro	Ser	Thr	Asp	Val	Gly
			20				25						30		
Ser	Asn	Thr	Tyr												
			35												

<210> 65

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
amylin peptide

<220>

<221> MOD_RES

<222> (2)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (7)

<223> Any amino acid

<400> 65

Lys	Xaa	Asn	Thr	Ala	Thr	Xaa	Ala	Thr	Gln	Arg	Leu	Thr	Asn	Phe	Leu
1				5					10					15	

Val Arg Ser Ser His Asn Leu Gly Ala Ala Leu Ser Pro Thr Asp Val
 20 25 30

Gly Ser Asn Thr Tyr
 35

<210> 66

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 amylin peptide

<220>

<221> MOD_RES

<222> (2)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (7)

<223> Any amino acid

<400> 66

Lys Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Thr Asn Phe Leu
 1 5 10 15

Val Arg Ser Ser His Asn Leu Gly Ala Ile Leu Pro Pro Thr Asp Val
 20 25 30

Gly Ser Asn Thr Tyr
 35

<210> 67

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 amylin peptide

<220>

<221> MOD_RES

<222> (2)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (7)

<223> Any amino acid

<400> 67

Lys	Xaa	Asn	Thr	Ala	Thr	Xaa	Ala	Thr	Gln	Arg	Leu	Thr	Asn	Phe	Leu
1				5				10						15	
Val	Arg	Ser	Ser	His	Asn	Leu	Gly	Pro	Ala	Leu	Pro	Pro	Thr	Asp	Val
			20				25						30		
Gly	Ser	Asn	Thr	Tyr											
			35												

Claims

1. An agonist analogue of amylin having the amino acid sequence:

¹A₁-X-Asn-Thr-⁵Ala-Thr-Y-Ala-Thr-¹⁰Gln-Arg-Leu-
¹⁵B₁-Asn-Phe-Leu-C₁-D₁-E₁-²⁰F₁-G₁-Asn-H₁-Gly-²⁵Pro-I₁-
³⁰Leu-Pro-J₁-Thr-K₁-Val-Gly-Ser-³⁵Asn-Thr-Tyr-Z

wherein

A₁ is Lys, Ala, Ser or hydrogen;
 B₁ is Ala, Ser or Thr;
 C₁ is Val, Leu or Ile;
 D₁ is His or Arg;
 E₁ is Ser or Thr;
 F₁ is Ser, Thr, Gln or Asn;
 G₁ is Asn, Gln or His;
 H₁ is Phe, Leu or Tyr;
 I₁ is Ile, Val, Ala or Leu;
 J₁ is Ser, Pro or Thr;
 K₁ is Asn, Asp or Gln;

X and Y are independently selected residues having side chains which are chemically bonded to each other to form an intramolecular linkage, wherein said intramolecular linkage comprises a disulfide bond, a lactam or a thioether linkage; and Z is amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy or aralkyloxy; and provided that when A₁ is Lys, B₁ is Ala, C₁ is Val, D₁ is Arg, E₁ is Ser, F₁ is Ser, G₁ is Asn, H₁ is Leu, I₁ is Val, J₁ is Pro, and K₁ is Asn; then one or more of A₁ to K₁ is not an L-amino acid and Z is not amino;

or a pharmaceutically acceptable salt thereof.

2. An agonist analogue of amylin according to claim 1 wherein X and Y comprise Cys residues linked by a disulfide bond.
3. An agonist analogue of amylin according to claim 2 wherein Z is amino.
4. An agonist analogue of amylin having the amino acid sequence:

¹A₁-X-Asn-Thr-⁵Ala-Thr-Y-Ala-Thr-¹⁰Gln-Arg-Leu-
¹⁵B₁-Asn-Phe-Leu-C₁-D₁-E₁-²⁰F₁-G₁-Asn-H₁-Gly-²⁵Pro-I₁-
³⁰Leu-J₁-Pro-³⁵Thr-K₁-Val-Gly-Ser-Asn-Thr-Tyr-Z

wherein

A₁ is Lys, Ala, Ser or hydrogen;
 B₁ is Ala, Ser or Thr;
 C₁ is Val, Leu or Ile;
 D₁ is His or Arg;
 E₁ is Ser or Thr;
 F₁ is Ser, Thr, Gln or Asn;
 G₁ is Asn, Gln or His;
 H₁ is Phe, Leu or Tyr;

I₁ is Ile, Val, Ala or Leu;
J₁ is Ser, Pro, Leu, Ile or Thr;
K₁ is Asn, Asp or Gln;

X and Y are independently selected residues having side chains which are chemically bonded to each other to form an intramolecular linkage, wherein said intramolecular linkage comprises a disulfide bond, a lactam or a thioether linkage; and Z is amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy or aralkyloxy; and provided that when

(a) A₁ is Lys, B₁ is Ala, C₁ is Val, D₁ is Arg, E₁ is Ser, F₁ is Ser, G₁ is Asn, H₁ is Leu, I₁ is Val, J₁ is Pro and K₁ is Asn; or
(b) A₁ is Lys, B₁ is Ala, C₁ is Val, D₁ is His, E₁ is Ser, F₁ is Asn, G₁ is Asn, H₁ is Leu, I₁ is Val, J₁ is Ser and K₁ is Asn;

then one or more of A₁ to K₁ not an L-amino acid and Z is not amino;
or a pharmaceutically acceptable salt thereof.

5. An agonist analogue of amylin according to claim 4 wherein X and Y comprise Cys residues linked by a disulfide bond.

6. An agonist analogue of amylin according to claim 5 wherein Z is amino.

7. An agonist analogue of amylin having the amino acid sequence:

¹A₁-X-Asn-Thr-⁵Ala-Thr-Y-Ala-Thr-¹⁰Gln-Arg-Leu-
B₁-Asn-¹⁵Phe-Leu-C₁-D₁-E₁-²⁰F₁-G₁-Asn-H₁-Gly-²⁵I₁-J₁-
Leu-Pro-Pro-³⁰Thr-K₁-Val-Gly-Ser-³⁵Asn-Thr-Tyr-Z

wherein

A₁ is Lys, Ala, Ser or hydrogen;
B₁ is Ala, Ser or Thr;
C₁ is Val, Leu or Ile;
D₁ is His or Arg;
E₁ is Ser or Thr;
F₁ is Ser, Thr, Gln or Asn;
G₁ is Asn, Gln or His;
H₁ is Phe, Leu or Tyr;
I₁ is Ala or Pro;
J₁ is Ile, Val, Ala or Leu;
K₁ is Asn, Asp or Gln;


X and Y are independently selected residues having side chains which are chemically bonded to each other to form an intramolecular linkage, wherein said intramolecular linkage comprises a disulfide bond, a lactam or a thioether linkage; and Z is amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy or aralkyloxy; and provided that when A₁ is Lys, B₁ is Ala, C₁ is Val, D₁ is Arg, E₁ is Ser, F₁ is Ser, G₁ is Asn, H₁ is Leu, I₁ is Pro, J₁ is Val and K₁ is Asn; then one or more of A₁ to K₁ is not an L-amino acid and Z is not amino;

or a pharmaceutically acceptable salt thereof.

8. An agonist analogue of amylin according to claim 7 wherein X and Y comprise Cys residues linked by a disulfide bond.

9. An agonist analogue of amylin according to claim 8 wherein Z is amino.

10. An agonist analogue of amylin having the amino acid sequence:



wherein

A₁ is Lys, Ala, Ser or hydrogen;

B₁ is Ala, Ser or Thr;

C₁ is Val, Leu or Ile;

D₁ is His or Arg;

E₁ is Ser or Thr;

F₁ is Ser, Thr, Gln or Asn;

G₁ is Asn, Gln or His;

H₁ is Phe, Leu or Tyr;

I₁ is Ile, Val, Ala or Leu;

J₁ is Asn, Asp or Gln;

X and Y are independently selected residues having side chains which are chemically bonded to each other to form an intramolecular linkage wherein said intramolecular linkage comprises a disulfide bond, a lactam or a thioether linkage; and Z is amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkoxy, aryloxy or aralkyloxy; and provided that when A₁ is Lys, B₁ is Ala, C₁ is Val, D₁ is Arg, E₁ is Ser, F₁ is Ser, G₁ is Asn, H₁ is Leu, I₁ is Val and J₁ is Asn; then one or more of A₁ to K₁ is not an L-amino acid and Z is not amino;

or a pharmaceutically acceptable salt thereof.

11. An agonist analogue of amylin according to claim 10 wherein X and Y comprise Cys residues linked by a disulfide bond.

12. An agonist analogue of amylin according to claim 11 wherein Z is amino.

13. An agonist analogue of amylin according to any of the preceding claims wherein D₁ is Arg.

14. An agonist analogue of amylin according to any of claims 1 to 6 or 10 to 12 wherein I₁ is Val.

15. An agonist analogue of amylin according to any one of claims 7 to 9 wherein J₁ is Val.

16. An agonist analogue of amylin according to any of the preceding claims wherein A₁ is hydrogen.

17. ¹⁸Arg^{25,28}Pro-h-amylin.

18. des-¹Lys¹⁸Arg^{25,28}Pro-h-amylin.

19. des-¹Lys^{25,28,29}Pro-h-amylin.

20. des-¹Lys¹⁸Arg^{25,28,29}Pro-h-amylin.

21. An agonist analogue of amylin according to any of the preceding claims which is an acetate, trifluoroacetate or hydrochloride salt.

22. An agonist analogue of amylin as defined in any one of the preceding claims for use in a method of treatment of the human or animal body for surgery or therapy or in diagnosis.

EP 1 162 207 A1

23. An agonist analogue of amylin according to claim 22 for use in the treatment of diabetes mellitus and symptoms thereof.

24. An agonist analogue of amylin according to claim 23 wherein the treatment comprises administration of an insulin.

25. A pharmaceutical composition comprising a therapeutically effective amount of an agonist analogue of amylin according to any one of claims 1 to 21.

26. A composition according to claim 25 including an insulin.

FIG. 1.

¹Lys-Cys-Asn-Thr-⁵Ala-Thr-Cys-Ala-Thr-¹⁰Gln-Arg-Leu-Ala-
 Asn-¹⁵Phe-Leu-Val-His-Ser-²⁰Ser-Asn-Asn-Phe-Gly-²⁵Ala-
 Ile-Leu-Ser-Ser-³⁰Thr-Asn-Val-Gly-Ser-³⁵Asn-Thr-Tyr-NH₂

FIG. 2.

Amylin

human

KdCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY-NH₂

cat	-----IR---L----P-----
dog	-----RT---L----P-----
rat	-----R---L-PV-PP-----
mouse	-----R---L-PV-PP-----
hamster	-----N--L-PV--P-----
guinea pig	-----T---R--H-L--A-LP-D-----

FIG. 3.

¹A₁-X-Asn-Thr-⁵Ala-Thr-Y-Ala-Thr-¹⁰Gln-Arg-Leu-
B₁-Asn-¹⁵Phe-Leu-C₁-D₁-E₁-²⁰F₁-G₁-Asn-H₁-Gly-²⁵I₁-J₁-
Leu-K₁-L₁-³⁰Thr-M₁-Val-Gly-Ser-³⁵Asn-Thr-Tyr-Z



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 11 4132

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IntCl.7)
E	WO 92 11862 A (AMYLIN PHARMACEUTICALS, INC.) 23 July 1992 (1992-07-23) see pages 19/20 and Table II	1-26	C07K14/575 A61K38/22
A	EP 0 408 294 A (AMYLIN CORPORATION) 16 January 1991 (1991-01-16) * page 7 *	1-26	
A	WO 89 06135 A (AMYLIN CORPORATION) 13 July 1989 (1989-07-13) * the whole document *	1-26	
A	EP 0 309 100 A (AMYLIN CORPORATION) 29 March 1989 (1989-03-29) * the whole document *	1-26	
A	GETTING DEEMS, R. ET AL.: "amylin or CGRP (8-37) fragments reverse amylin-induced inhibition of 14C-glycogen accumulation" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, pages 116-120, XP002178590 * the whole document *	1-26	TECHNICAL FIELDS SEARCHED (Int.Cl.7) C07K
A	WESTERMARK, P. ET AL.: "Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation" PROC. NATL. ACAD. SCI., vol. 87, July 1990 (1990-07), pages 5036-5040, XP000137094 see especially Figures 1 and 4; Table 1 -/--	1-26	
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 16 October 2001	Examiner Kurz, B
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1505 03.92 (PatCat)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 11 4132

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	NISHI, M. ET AL.: "Conservation of the sequence of islet amyloid polypeptide in five mammals is consistent with its putative role as an islet hormone" PROC. NATL. ACAD. SCI., vol. 86, August 1989 (1989-08), pages 5738-5742, XP001019238 see especially Figures 4 and 5 -----	1-26	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 16 October 2001	Examiner Kurz, B
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/02 (P0401)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 11 4132

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

16-10-2001

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9211862	A	23-07-1992	US 5234906 A	10-08-1993
			AT 155689 T	15-08-1997
			AU 641855 B2	30-09-1993
			AU 1328692 A	17-08-1992
			CA 2076658 A1	11-07-1992
			CA 2077265 A1	11-07-1992
			DE 69221040 D1	04-09-1997
			DE 69221040 T2	13-11-1997
			DK 525149 T3	01-12-1997
			EP 0525149 A1	03-02-1993
			EP 0525158 A1	03-02-1993
			ES 2107528 T3	01-12-1997
			GR 3024812 T3	30-01-1998
			JP 2818296 B2	30-10-1998
			SG 43866 A1	14-11-1997
			WO 9211862 A1	23-07-1992
			WO 9211863 A1	23-07-1992
			US 5508260 A	16-04-1996
			US 5527771 A	18-06-1996
			US 6048514 A	11-04-2000
			US 5321008 A	14-06-1994
			ZA 9200005 A	31-03-1993
EP 0408294	A	16-01-1991	AT 128032 T	15-10-1995
			AU 620727 B2	20-02-1992
			AU 5953790 A	06-02-1991
			CA 2020786 A1	11-01-1991
			DE 69022501 D1	26-10-1995
			DE 69022501 T2	01-02-1996
			DK 408294 T3	15-01-1996
			EP 0408294 A2	16-01-1991
			ES 2080802 T3	16-02-1996
			GR 3018442 T3	31-03-1996
			IE 902514 A1	13-02-1991
			JP 4500688 T	06-02-1992
			NO 910901 A	25-04-1991
			NZ 234428 A	22-08-1997
			US 5364841 A	15-11-1994
			WO 9100737 A1	24-01-1991
			US 5280014 A	18-01-1994
WO 8906135	A	13-07-1989	AT 128359 T	15-10-1995
			AU 631112 B2	19-11-1992
			AU 2949489 A	01-08-1989
			DE 68924372 D1	02-11-1995
			DE 68924372 T2	09-05-1996

EPO FORM PUS-89

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 11 4132

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

16-10-2001

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 8906135	A		DK 443889 A	27-10-1989
			EP 0348490 A1	03-01-1990
			FI 950530 A	07-02-1995
			HK 1002990 A1	30-09-1998
			JP 10267914 A	09-10-1998
			JP 3501611 T	11-04-1991
			NO 893606 A	13-11-1989
			NO 951250 A	13-11-1989
			NZ 227601 A	23-12-1991
			US 5364841 A	15-11-1994
			WO 8906135 A1	13-07-1989
			US 5716619 A	10-02-1998
			US 5942227 A	24-08-1999
			US 5266561 A	30-11-1993
			US 5280014 A	18-01-1994
			US 5281581 A	25-01-1994
EP 0309100	A	29-03-1989	AT 155688 T	15-08-1997
			AU 634954 B2	11-03-1993
			AU 2157588 A	20-07-1989
			DE 3855970 D1	04-09-1997
			DE 3855970 T2	29-01-1998
			DK 473888 A	05-04-1989
			EP 0309100 A2	29-03-1989
			EP 0787741 A1	06-08-1997
			ES 2106721 T3	16-11-1997
			FI 883936 A	27-02-1989
			GR 3024705 T3	31-12-1997
			HK 1000934 A1	08-05-1998
			JP 1096137 A	14-04-1989
			JP 2828250 B2	25-11-1998
			NO 883828 A	27-02-1989
			US 5641744 A	24-06-1997
			US 5367052 A	22-11-1994
			US 5124314 A	23-06-1992

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82